Swiss-listed Newron Pharmaceuticals on Friday said late-stage tests suggested that its brain drug safinamide improves cognitive performance in patients with early Parkinson's disease.
German-Swiss group Merck Serono has exclusive worldwide rights to develop, make and sell safinamide for Parkinson's disease, Alzheimer's disease, and other cognitive disorders following an agreement with Newron last October.
The Phase III data show that adding safinamide to dopamine treatments resulted in an improvement in cognitive functions, Newron said in a statement.
Those functions include working memory and ability for planning, organizing, strategizing and paying attention and remembering details.
The data were presented at a Movement Disorder Society's congress in Istanbul.
source : news.yahoo.com
Friday, June 8, 2007
Newron says brain drug helps Parkinsons' patients
Labels: health care insurance
Posted by kayonna at 3:38 AM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment